The purpose of the study is to explore and compare how effectively these two imaging methods can find tumors. Patients will receive both types of scans, and the results will be compared to see which method is better at detecting the cancer. The study will also look at how the cancer appears in these scans compared to a standard imaging method called computed tomography (CT), which uses X-rays to create detailed pictures of the inside of the body.

During the study, patients will undergo these imaging tests, and the results will be analyzed to determine the best way to detect tumors in this type of kidney cancer. The study will help doctors understand which imaging method provides the most accurate information about the presence and spread of the cancer, potentially leading to better diagnosis and treatment options for patients with metastatic renal cell carcinoma.

The purpose of the study is to evaluate how delaying the removal of the primary tumor affects the survival of patients who are receiving these treatments. Participants will be randomly assigned to either have the tumor removed or not, while continuing their current treatment. The study will last for a period of up to 36 months, during which the effects of the treatments on the patients’ overall survival and progression-free survival will be monitored. Progression-free survival refers to the length of time during and after treatment that a patient lives with the disease without it getting worse.

Additionally, the study will assess the safety of the surgical procedure and its impact on the quality of life of the patients. Quality of life will be evaluated using specific questionnaires. The study will also look at how different treatment strategies affect the proteins in the body and how these changes relate to treatment outcomes. This research aims to provide valuable insights into the best treatment approaches for patients with metastatic renal cell carcinoma.

The purpose of the study is to see if taking a break from these treatments is as effective as continuing them for patients who have responded well to the treatment after about a year. Participants in the study will be randomly assigned to either pause or continue their treatment. The study will monitor the participants’ health and cancer status over time to see if the cancer stays under control without the treatment. The study will last for up to 24 months, and participants will have regular check-ups and assessments to track their progress.

Throughout the study, researchers will look at various aspects, such as how many participants do not experience cancer progression, the side effects of the treatments, and the overall quality of life of the participants. The study aims to provide valuable information on whether a treatment pause can be a safe and effective option for patients with mRCC who have responded well to initial treatment.

Participants in the study will receive either the folic acid supplement or a placebo. The study will monitor the degree of mucositis experienced by participants, using a standard set of criteria known as the Common Terminology Criteria for Adverse Events (CTCAE). The study will also collect information on how often and how severe the mucositis is, based on patient self-assessments. Additionally, the study will look at other factors such as the need for dose reductions or discontinuations of cancer treatments, and the overall quality of life of participants.

The trial is expected to run until 2026, and it aims to provide valuable insights into whether folic acid can be an effective way to manage mucositis in patients undergoing treatment for metastatic renal cell carcinoma. This could potentially improve the comfort and quality of life for patients dealing with this challenging side effect of cancer therapy.

Participants in the study will receive pembrolizumab, and some may receive a placebo. The study will compare the outcomes of those who receive pembrolizumab with those who do not, to determine if the medication is effective in extending the time before the cancer progresses. The study will also look at how long patients live after treatment and monitor any side effects that may occur. The trial is expected to continue for several years to gather enough information to make these assessments.

Throughout the study, patients will undergo regular check-ups and imaging tests to monitor the status of their cancer. These tests will help doctors understand how the cancer is responding to the treatment. The ultimate goal is to find out if pembrolizumab can improve the quality of life and survival for patients with this type of kidney cancer.

The purpose of this study is to evaluate how well the combination of axitinib and pembrolizumab works compared to axitinib alone in treating patients with this type of kidney cancer. Participants in the study will receive either the combination of both medications or axitinib by itself. The study will monitor the response to the treatment over a period of time to see which approach is more effective. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.

Throughout the study, participants will have regular visits to the clinic for treatment and monitoring. This will include receiving the medication, having blood tests, and undergoing other necessary procedures to ensure their safety and to track the progress of the treatment. The study aims to provide valuable information on the best treatment options for patients with papillary renal cell carcinoma.

The purpose of the study is to explore how effective the combination of axitinib and nivolumab is compared to nivolumab alone in treating patients with mRCC who have not had a complete response to the initial treatment. Participants will receive either the combination of axitinib and nivolumab or nivolumab alone. The study will last for a period of up to 12 months, during which the effects of the treatments will be monitored.

Throughout the study, researchers will evaluate various outcomes, such as how well the cancer responds to the treatments, the length of time patients live without the cancer getting worse, and the overall survival of the patients. Additionally, the study will assess the safety of the treatments and their impact on the quality of life of the participants. The findings from this study aim to provide valuable insights into the treatment of metastatic renal cell carcinoma.

The purpose of this study is to determine whether the combination of Nivolumab and Cabozantinib is more effective and safe compared to Sunitinib in treating patients who have not received any prior treatment for their advanced or metastatic kidney cancer. Participants in the study will be randomly assigned to receive either the combination treatment or Sunitinib. The study will monitor the participants over a period to assess the progression of the disease and any side effects experienced.

Throughout the study, participants will receive their assigned treatment and undergo regular check-ups to track their health and the cancer’s response to the treatment. The study will help researchers understand which treatment option provides better outcomes for patients with this type of kidney cancer. A placebo may be used in some parts of the study to compare the effects of the actual medications. The study is expected to continue until 2025, providing valuable insights into the treatment of advanced or metastatic renal cell carcinoma.

The purpose of the study is to evaluate how well these combinations work and how safe they are for patients. Participants will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will compare different groups of patients receiving different combinations of these drugs. One group will receive Tobemstomig and Axitinib, another will receive Tiragolumab, Tobemstomig, and Axitinib, and a control group will receive Pembrolizumab and Axitinib. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual drugs.

The study will take place over a period of up to 24 months, during which participants will be monitored for any changes in their condition and any side effects they may experience. The goal is to determine which combination of treatments is most effective in slowing down the progression of the cancer and to assess the overall safety of these treatments. Participants will be closely observed by medical professionals throughout the study to ensure their well-being and to gather important data on the treatments being tested.

The purpose of the study is to evaluate how well the new treatment combination works and how safe it is for patients. Participants in the study will receive either the new treatment or one of the standard treatments. The study will monitor the response of the cancer to the treatment and any side effects that may occur. The new treatment involves the use of pembrolizumab, which is given through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. Epacadostat is taken orally, which means it is swallowed in pill form. The standard treatments, sunitinib and pazopanib, are also taken orally.

The study will take place over a period of time, during which participants will be regularly monitored by healthcare professionals. The goal is to determine if the new treatment combination can provide better outcomes for patients with this type of kidney cancer compared to the standard treatments. Participants will be closely observed for any changes in their condition and any side effects they may experience during the course of the study.

The purpose of this study is to compare how well patients with advanced kidney cancer respond to the combination of pembrolizumab and axitinib versus those who receive only sunitinib. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. The study will monitor the participants over a period to see how the cancer responds to the treatments and to check for any side effects.

Throughout the study, participants will receive regular check-ups and assessments to track their health and the progress of their cancer. The study aims to provide valuable information on which treatment option might be more effective for patients with this type of kidney cancer. The trial is expected to continue until the end of 2025, allowing researchers to gather comprehensive data on the treatments’ long-term effects.

The purpose of the study is to compare how well these treatments work in terms of how long patients live and how long they live without the cancer getting worse. Participants in the study will be randomly assigned to one of the two treatment groups. The study will follow participants over a period of time to monitor their health and the effects of the treatments. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for people with advanced or metastatic renal cell carcinoma. This research could help improve future treatment options for this type of cancer.